BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...as managing director at C-Bridge Capital (now CBC Group...
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...saw participation from the company’s founding investor, CBC Group...
...employees: 80Funds raised: At least $170 millionInvestors: CBC Group...
...Dayao ZhaoPatents: N/A Jeff Cranmer AffaMed Therapeutics (Shanghai) Co. Ltd. CBC Group Lake...
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...past nine years at bluebird bio Inc. (NASDAQ:BLUE), will be stepping down on April 16. Investment firm CBC Group...
...and general counsel at Sarepta Therapeutics Inc. (NASDAQ:SRPT). Gunjan Ohri Agilent Technologies Inc. Turning Point Therapeutics Inc. Moderna Inc. CareDx Inc. CBC Group Intercept...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...for $300M fund brings in royalty streams for Paratek’s Nuzyra By Paul Bonanos, Associate Editor CBC Group...
...New York, Shanghai, Hong Kong and Beijing. Paul Bonanos Nuzyra, omadacycline (ZL-2401, ptk 0796, BAY 73-7388, MK-2764, PTK796) CBC Group Paratek...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...series D round led by RTW Investments and GT Fund with participation by existing investors CBC Group...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...and Co. (NYSE:LLY), Blanchard was with Innovent for about 18 months in 2018-19. He joined CBC Group...
...including those in its $310 million series C round in June, also participated in the IPO.CBC Group...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...C-2 equity round, which also included RA Capital, Hillhouse Capital, Decheng Capital, ZJMF, Janus Henderson, CBC Group...
...Lilly and Co. (NYSE:LLY), was CSO at Innovent Biologics Inc. (HKSE:1801) in 2018-19 before joining CBC Group...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group...
...as CSO of Innovent Biologics Inc. (HKEX:1801). Cao, who is also a managing director at CBC Group...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...retiring, as CFO. Cooper was finance director at Kennet Partners Ltd. Kerry Blanchard has joined CBC Group...
...Inc. Verseau Therapeutics Inc. Flagship Pioneering Inozyme Pharma Inc. Theragnostics Ltd. Prescient Medicine Holdings Inc. Orion Biotechnology Canada Ltd. Arrowhead Pharmaceuticals Inc. Abingworth LLP CBC Group Diverse...
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...In China, 3SBio Inc. (HKSE:1530) holds rights to SB8, a biosimilar of Avastin bevacizumab, while CBC Group...
Items per page:
1 - 10 of 21
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...as managing director at C-Bridge Capital (now CBC Group...
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...saw participation from the company’s founding investor, CBC Group...
...employees: 80Funds raised: At least $170 millionInvestors: CBC Group...
...Dayao ZhaoPatents: N/A Jeff Cranmer AffaMed Therapeutics (Shanghai) Co. Ltd. CBC Group Lake...
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...past nine years at bluebird bio Inc. (NASDAQ:BLUE), will be stepping down on April 16. Investment firm CBC Group...
...and general counsel at Sarepta Therapeutics Inc. (NASDAQ:SRPT). Gunjan Ohri Agilent Technologies Inc. Turning Point Therapeutics Inc. Moderna Inc. CareDx Inc. CBC Group Intercept...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...for $300M fund brings in royalty streams for Paratek’s Nuzyra By Paul Bonanos, Associate Editor CBC Group...
...New York, Shanghai, Hong Kong and Beijing. Paul Bonanos Nuzyra, omadacycline (ZL-2401, ptk 0796, BAY 73-7388, MK-2764, PTK796) CBC Group Paratek...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...series D round led by RTW Investments and GT Fund with participation by existing investors CBC Group...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...and Co. (NYSE:LLY), Blanchard was with Innovent for about 18 months in 2018-19. He joined CBC Group...
...including those in its $310 million series C round in June, also participated in the IPO.CBC Group...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...C-2 equity round, which also included RA Capital, Hillhouse Capital, Decheng Capital, ZJMF, Janus Henderson, CBC Group...
...Lilly and Co. (NYSE:LLY), was CSO at Innovent Biologics Inc. (HKSE:1801) in 2018-19 before joining CBC Group...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group...
...as CSO of Innovent Biologics Inc. (HKEX:1801). Cao, who is also a managing director at CBC Group...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...retiring, as CFO. Cooper was finance director at Kennet Partners Ltd. Kerry Blanchard has joined CBC Group...
...Inc. Verseau Therapeutics Inc. Flagship Pioneering Inozyme Pharma Inc. Theragnostics Ltd. Prescient Medicine Holdings Inc. Orion Biotechnology Canada Ltd. Arrowhead Pharmaceuticals Inc. Abingworth LLP CBC Group Diverse...
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...In China, 3SBio Inc. (HKSE:1530) holds rights to SB8, a biosimilar of Avastin bevacizumab, while CBC Group...
Items per page:
1 - 10 of 21